ArticleGeroScience2026
Association between atrial fibrillation and systemic inflammation with muscle mass and strength trajectories in old age.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The long-term impact of atrial fibrillation (AF) and systemic inflammation on muscle health and, hence, functional decline remains unclear. This study investigates the link between AF and longitudinal trajectories of muscle mass and strength, considering the role played by systemic inflammation. Data were obtained from 2048 participants (≥ 60 years) in the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), followed for 12 years. Muscle mass and strength were assessed using calf circumference, handgrip strength, and chair stand test. Inflammatory marker interleukin-6 (IL-6) and the stress-response mediator growth differentiation factor-15 (GDF-15) were measured at baseline. Linear mixed models examined the longitudinal changes in muscle outcomes according to AF status and the combination of AF status with inflammatory markers. Participants with AF experienced a steeper increase in the duration of the chair stand test (β = 1.49; 95% CI: 0.82 to 2.16). High levels of GDF-15 amplified declines in muscle mass (β = - 0.12; 95% CI: - 0.20 to - 0.05) and chair stand test performance (β = 2.48; 95% CI: 1.66 to 3.30) in individuals with AF. Participants with AF and high IL-6 levels also experienced an accelerated decline of calf circumference (β = - 0.12; 95% CI: - 0.19 to - 0.05) and chair stand test performance (β = 2.20; 95% CI: 1.39 to 3.01). AF is associated with a steeper decline in muscle mass and strength over time, exacerbated by elevated inflammatory biomarkers, underscoring the importance of systemic inflammation in AF-related functional decline.
Indexed as
Identifiers
42337156What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.